期刊文献+

P^(16)和PCNA在食管癌中的表达及意义 被引量:1

The expression and significance of P^(16) and PCNA in esophageal cancer.
下载PDF
导出
摘要 陕西省肿瘤医院 ,西安  71 0 0 612 陕西省人民医院 ,西安  71 0 0 68目的 观察抑癌基因P16、增殖细胞核抗原PCNA在食管鳞状细胞癌中的表达特性及与临床病理联系。方法 应用SP免疫组织化学方法。结果 在 6 4例食管鳞癌中P16阳性表达率为 6 8 9% ,PCNA阳性细胞增殖指数 (PCNA PI)平均值 5 3 4。P16在低分化癌中较高分化癌阳性表达率低 ,相反 ,PCNA PI在高分化癌平均值低 ,在低分化癌高 (P <0 0 5 )。有淋巴结转移的P16阳性表达率低 ,且随着病期的进展阳性表达率降低 (P <0 0 5 )。P16阴性组PCNA PI高 (P >0 0 5 )。结论 联合检测P16蛋白和PCNA蛋白对食管鳞癌恶性度评定 ,治疗的选择 。 Objective To investigate the expression of anti oncogene P 16 and proliferative cell nuclear antigen (PCNA) in esophageal squamous cell cancer and their clinical pathology.Methods The SP immunohistochemistry method was used in the study.Results The positive P 16 expression was found in the 68.9% of the total 64 cases of esophageal squamous cell cancer, the average PCNA positive cell proliferation incidence(PCNA PI) was 53.4%. P 16 expression was very low in the poorly differentiated esophageal cancer. In contrast, the average PCNA PI was low in highly differentiated cancer cells, while being high in the poorly differentiated cells (P<0 05). Low P 16 expression was found while there was lymph node metastasis and as the cancer developed, the percentage of P 16 positive cell decreased (P<0 01). PCNA PI was low in the P 16 positive group and was high in the P 16 negative group (P>0 05).Conclusion Combined examination of the P 16 and PCNA is of great significance in determining the malignancy state, therapy method and evaluating the prognosis of the esophageal squamous cell cancer.
出处 《陕西肿瘤医学》 2001年第2期100-102,共3页 ShanXi Oncology Medicine
关键词 食管鳞癌 增殖细胞核抗原 抑癌基因 SP免疫组织化学方法 esophageal squamous cell cancer P 16 proliferative cell nuclear antigen immunohistochemistry
  • 相关文献

参考文献6

  • 1Tarmin L, Yin J, Zhou X,et al. Trequent loss of hetero-zygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus[J]. Cancer Res, 1994,54:6094~6096.
  • 2Serrano M, Harmon J, Beach A. A new regulatory motief in cell cycle control cansing specific inhibition of cyclin S/CDK4[J]. Nature, 1993,366:704~707.
  • 3Vigliemi MC,Chio A, Peggule T,et al. Proliferating cell nucler antige(PCNA) in low gradeastroeytomas:its prognostic significance[J]. Tumori, 1994,80(4):295.
  • 4Al-Sheneber IF, Shibata HR, Sampalis J,et al. Prognostic siginificance of proliferating cell nucle antigen expression in colorectal cancer[J]. Cancer, 1993,71(6):1954.
  • 5池田公正,田卓士,江正树,他.大肠癌にわけるCyclin D1,CD4,CDK4-inhibitor(P16)四发现[J].日临,1996,54:1054~1059.
  • 6Carcia PL, Coltrera MD, Gown AM. Analysis of proliferative grade using anti-PCNA cyclin monoelonal antibodies in fixed embedded tissues, Comparison with flow cytometric amalysis[J]. Am J Pathal,1989,134(2):733.

同被引文献9

  • 1[1]Reeves ME, DeMatteo RP. Genes and viruses in hepatobilitary neoplasia[J]. Semin Surg Oncol,2000,19(2) :84.
  • 2[2]Trere D, Chieco P, Lacchini M, et al .In human hepatocellular carcinoma in cirrhosis proliferating cell nuclear antigen (PCNA) is involved in cell proliferation and cooperates with P21 in DNA repair[J]. J Hepatol, 2003, 39(6) :997 ~ 1003.
  • 3[3]Ioachim E, Michael M, Stavropoulos NE, et al. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21 ( Wafl/Cipl ) and p27 ( Kipl ) in urothelial carcinoma: correlation with other cell- cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features[J]. Urol Int, 2004,73(1) :65 ~ 73.
  • 4[4]Lee TK, Man K, Poon RT, et al. Disruption of p53-p21/WAF1 cell cycle pathway contributes to progression and worse clinical outcome of hepatocellular carcinoma[J]. Oncol Rep,2004 , 12( 1 ) :25 ~ 31.
  • 5[5]Can B, Sokmensuer C. Clinicopathologic features, cellular differentiation, PCNA and P53 expressions in gastrointestinal stromal tumors[J].Hepatogastroenterology, 2003, 50 Suppl 2: ccxliii ~ ccxlviii.
  • 6[6]Buyukbayram H, Cureoglu S, Arslan A, et al. Prognostic value of PCNA and mutant p53 expression in laryngeal squamous cell carcinoma [J]. Cancer Invest,2004,22(2): 195 ~ 202.
  • 7[7]Nanashima A, YanoH, Yamaguchi H, et al. Immunohistochemical analysis of tumor biological factors in hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection[ J]. J Gastroenterol,2004,39(2): 148 ~ 154.
  • 8[8]Osada S, Saji S, Kuno T. Clinical significance of combination study of apopto ic factors and proliferating cell nuclear antigen in estimating the prognosis of hepatocellular carcinoma[J]. J Surg Oncol,2004,85(1):48~54.
  • 9张吉成,王晓敏,曹原理,梁爱琳,刘宁娜,石景森.CD44V6和PCNA在大肠癌粘液性癌和非粘液性癌中的表达及意义[J].陕西肿瘤医学,2001,9(1):8-9. 被引量:1

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部